- The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 26% pre-market today. This is why.
The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) – a global healthcare leader developing and producing patented Microcyn technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions – increased by over 26% pre-market today. Investors are responding positively to Sonoma Pharmaceuticals announcing that it has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa.
Microdox is a super-oxidized solution based on Sonoma’s patented Microcyn Technology intended to treat and prevent infections in the urinary tract and bladder. And Microdox is a non-irritating and non-toxic solution and is ready for immediate use. Microdox is currently available through Sonoma’s partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.
“We believe Microdox is a unique bladder irrigation that fulfills the requirements of an effective adjunct UTI prevention and treatment for the removal of UTI-causing bacteria, bacterial biofilms, and drug-resistant strains.”
— Scott Lissington, COO of Te Arai BioFarma
“We look forward to the benefits that Microdox will offer in the prevention and treatment of urinary tract infections to health care professionals. This is a revolutionary treatment to patients that have been struggling with complicated, antibiotic resistant and recurrent UTIs.”
— Lindsay Shahim, Director of NuAngle
“We are pleased to bring our partners this new indication for Microdox® that will help reduce urinary tract infections for their patients. Through the science and development of Microcyn Technology our aim is to improve the quality of life for patients, including those that require a bladder and catheter rinse. Our proprietary Microcyn® technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety.”
— Bruce Thornton, COO of Sonoma Pharmaceuticals
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.